v3.19.3
Note 1 - Organization and Basis of Presentation (Details Textual)
1 Months Ended
May 31, 2019
USD ($)
May 03, 2019
May 31, 2019
USD ($)
Apr. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Cash and Cash Equivalents, at Carrying Value, Ending Balance         $ 24,000 $ 1,887,000 $ 4,301,000
Loans Payable, Total           4,200,000  
Retained Earnings (Accumulated Deficit), Ending Balance         (44,417,000) $ (37,279,000) $ (31,294,000)
Majority Investors [Member]              
Debt Instrument, Interest Rate, Stated Percentage           8.00%  
Majority Investors [Member] | First Note to Fund the Company's Operations [Member]              
Proceeds from Notes Payable, Total       $ 2,000,000      
Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]              
Proceeds from Notes Payable, Total $ 500,000   $ 500,000        
Majority Investors [Member] | Notes to Fund the Company's Operations [Member]              
Debt Instrument, Interest Rate, Stated Percentage 8.00%   8.00%        
Convertible Debt [Member]              
Notes Payable, Total         5,600,000 $ 4,600,000  
Oxford Finance, LLC [Member]              
Loans Payable, Total         $ 3,000,000    
Reverse Stock Split From [Member] | Alliqua Biomedical, Inc. [Member]              
Stockholders' Equity Note, Stock Split, Conversion Ratio   6          
Alliqua Biomedical, Inc. [Member]              
Business Acquisition, Exchange Ratio   0.0359